Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12612000345886
ACTRN12612000345886
Recruiting
未知

Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer

udwig Institute for Cancer Research0 sites100 target enrollmentMarch 26, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients with resectable colorectal cancer liver metastasesCancer - Bowel - Back passage (rectum) or large bowel (colon)

Overview

Phase
未知
Intervention
Not specified
Conditions
Patients with resectable colorectal cancer liver metastases
Sponsor
udwig Institute for Cancer Research
Enrollment
100
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 26, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
udwig Institute for Cancer Research

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with histologically confirmed primary colorectal cancer
  • •2\. Patients with resected primary tumours or planned for curative primary tumour resection.
  • •3\. Patients with resectable liver metastases following workup including CT scans of chest, abdomen and pelvis (or MRI if unable to undertake CT scan) and whole body PET scan.
  • •4\. Patients fit for surgery
  • •5\. Patients fit for combination chemotherapy (5\-FU and oxaliplatin)
  • •6\. Patients willing to provide written informed consent

Exclusion Criteria

  • •1\. History of another primary cancer within the last 5 years, with the exception of non\-melanomatous skin cancer and carcinoma in situ of the cervix.
  • •2\. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
  • •3\. Patients that are not accessible for follow\-up

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Circulating Tumour DNA as a Marker of Complete Pathological Response and Long Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative Chemoradiotherapy
ACTRN12612000327886udwig Institute for Cancer Research320
Active, not recruiting
Phase 1
CIRCULATE - A TRIAL TO IMPROVE CARE OF PATIENTS AFTER COLON TUMOR SURGERY, BASED ON AN INNOVATIVE MARKER: CIRCULATING TUMOR DNAstage II colon cancer, after tumour resectionTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-000935-15-FRCentre Hospitalier Universitaire (CHU) de Dijon1,980
Recruiting
Not Applicable
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancer
NL-OMON24467Erasmus Medical Center95
Recruiting
Phase 1
Dynamics of circulating tumor DNA (ctDNA) and extracellular vesicle (EVs) for diagnosis, therapy monitoring, and prognosis assessment in solid visceral tumors.C15C18C19C22C23C24C25C26C49C16C48.2Malignant neoplasm of oesophagusMalignant neoplasm of colonMalignant neoplasm of rectosigmoid junctionMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of gallbladderMalignant neoplasm of other and unspecified parts of biliary tractMalignant neoplasm of pancreasMalignant neoplasm of other and ill-defined digestive organsMalignant neoplasm of other connective and soft tissueMalignant neoplasm of stomachPeritoneum, unspecified
DRKS00028154niversitätklinikum Münster (UKM) Klinik füt Allgemein-, Viszeral- und Transplantationschirurgie. Direktor: Univ.-Prof. Dr. med. A. Pascher, MBA, FEBS100
Recruiting
Not Applicable
Circulating tumor DNA as a noninvasive biomarker in patients with thyroid cancerC73Malignant neoplasm of thyroid gland
DRKS00022441niversitätsklinikum Freiburg75